Here are the S-3 shelf registrations from Zenas BioPharma, Inc. (ZBIO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow ZBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZBIO filings page.
Zenas BioPharma, Inc. (ZBIO) has filed an automatic shelf registration statement on Form S-3 to register the resale of up to 7,000,000 already-issued shares of common stock held by InnoCare Pharma Inc. The company is not offering any shares and will not receive proceeds from these sales; all proceeds go to the selling stockholder, while Zenas bears the registration costs.
The shares were issued to InnoCare under a broader strategic relationship, including an October 2025 license agreement for orelabrutinib and early-stage candidates ZB021 and ZB022, and related subscription and registration rights agreements. Zenas paid $35.0 million in upfront cash and issued 5,000,000 shares initially, then upon an August 2026 regulatory milestone became obligated to pay an additional $25.0 million and issue 2,000,000 more shares. InnoCare’s transfers are contractually volume-limited after an initial lock-up ending October 7, 2026.
Zenas highlights its immunology and inflammation pipeline led by obexelimab, which met the primary and key secondary endpoints in a Phase 3 IgG4‑RD trial and has a BLA accepted by the FDA with a PDUFA target date of May 27, 2027. The filing confirms Zenas’ status as a well-known seasoned issuer and outlines extensive forward‑looking risks tied to clinical progress, regulatory outcomes, financing needs and market conditions.